FDA Approves Sotyktu for Psoriatic Arthritis After Phase 3 Shows 54% ACR20
The FDA approved Bristol Myers Squibb’s oral Sotyktu for adult psoriatic arthritis after Phase 3 trials showed 54% of patients achieving ACR20 at week 16 versus 34%–39% with placebo. The approval expands Sotyktu’s label beyond plaque psoriasis, potentially broadening its immunology franchise and revenue base.
1. FDA Approval Details
The FDA granted approval for Bristol Myers Squibb’s oral Sotyktu at a 6 mg daily dose to treat adults with active psoriatic arthritis, marking its second indication after moderate-to-severe plaque psoriasis. This clearance enables physicians to target TYK2-mediated inflammation across both skin and joint manifestations.
2. Phase 3 Trial Results
In the POETYK PsA-1 and PsA-2 studies, about 54% of patients on Sotyktu achieved an ACR20 response by week 16 versus 34% and 39% on placebo. Approximately 25% of treated patients reached ACR50, and minimal disease activity scores improved across joint, skin, and patient-reported pain measures.
3. Market Impact and Safety Profile
The expanded label could drive significant revenue upside by broadening Sotyktu’s addressable patient population, with psoriatic arthritis affecting up to 30% of psoriasis patients. Safety data aligned with prior studies, showing respiratory infections, mouth ulcers, and elevated muscle enzymes, with tuberculosis screening required before initiation.